Table 3.
Multivariate survival analysis by tumor localization, adjusted for age and gender
| |
|
Tumor Localization |
|||||
|---|---|---|---|---|---|---|---|
| |
|
Colon |
Rectal |
||||
| Clinical endpoint | Covariate | HR | 95% CI | p-value | HR | 95% CI | p-value |
|
OS |
ERCC1
-19q13 |
0.32 |
0.14-0.75 |
0.01 |
0.82 |
0.35-1.95 |
0.66 |
|
ERCC1
-19q13/CEN-2 |
0.37 |
0.16-0.83 |
0.02 |
1.01 |
0.425-2.25 |
0.98 |
|
|
ERCC1
-19q13 gain |
0.45 |
0.20-1.00 |
0.049 |
1.01 |
0.59-1.75 |
0.97 |
|
|
TTR |
ERCC1
-19q13 |
0.34 |
0.12-1.00 |
0.0499 |
0.87 |
0.36-2.15 |
0.77 |
|
ERCC1
-19q13/CEN-2 |
0.24 |
0.09-0.70 |
0.01 |
0.87 |
0.36-2.14 |
0.77 |
|
|
ERCC1
-19q13 gain |
0.42 |
0.16-1.07 |
0.07 |
1.00 |
0.56-1.77 |
0.99 |
|
|
LR
a
|
ERCC1
-19q13 |
- |
- |
- |
0.68 |
0.20-2.28 |
0.53 |
|
ERCC1
-19q13/CEN-2 |
- |
- |
- |
0.91 |
0.28-3.04 |
0.88 |
|
| ERCC1 -19q13 gain | - | - | - | 0.73 | 0.33-1.60 | 0.42 | |
aRectal cancer patients only.